| Date Filed | Type | Description |
| 03/13/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/02/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/14/2023 |
SC 13G
| GLAZER CAPITAL, LLC reports a 9.6% stake in Ibere Pharmaceuticals |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/31/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 5.6% stake in Ibere Pharmaceuticals |
| 02/08/2022 |
SC 13G
| PIPV Capital LLC reports a 20% stake in Ibere Pharmaceuticals |
| 01/14/2022 |
SC 13G
| Magnetar Financial LLC reports a 5.8% stake in IBERE PHARMACEUTICALS |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 09/27/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/16/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/16/2021 |
10-Q/A
| Quarterly Report for the period ended March 31, 2021 [amend] |
| 08/16/2021 |
8-K/A
| Quarterly results |
| 08/13/2021 |
8-K
| Quarterly results |
| 08/04/2021 |
8-K
| Quarterly results |
| 07/16/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 05/28/2021 |
8-K
| Quarterly results |
| 05/18/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 03/12/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/08/2021 |
8-K
| Quarterly results |
| 03/03/2021 |
8-K
| Quarterly results |
| 03/02/2021 |
4
| Vollmer Louis J. (Director) has filed a Form 4 on IBERE PHARMACEUTICALS|
Txns:
| Bought 10,000 units
@ $10, valued at
$100k
|
|
| 03/01/2021 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 02/25/2021 |
3
| Kerekes Zoltan (COO) has filed a Form 3 on IBERE PHARMACEUTICALS |
| 02/25/2021 |
3
| PIPV Capital LLC (10% Owner) has filed a Form 3 on IBERE PHARMACEUTICALS |
| 02/25/2021 |
3
| IMASOGIE OSAGIE O (CEO) has filed a Form 3 on IBERE PHARMACEUTICALS |
| 02/25/2021 |
3
| Vollmer Louis J. (Director) has filed a Form 3 on IBERE PHARMACEUTICALS |
| 02/25/2021 |
3
| Gray Lisa M. (CFO) has filed a Form 3 on IBERE PHARMACEUTICALS |
| 02/25/2021 |
3
| UKWU HENRIETTA (Director) has filed a Form 3 on IBERE PHARMACEUTICALS |
|